Flash Finance

Bafna Pharmaceuticals LimitedBAFNAPHCorporate

Pharmaceuticals - Indian - Formulations Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹461.35
MCap ₹1,091 Cr · P/E 140.2
Bafna Pharmaceuticals Limited — Stock analysis & AI research Bafna Pharmaceuticals Limited — Seasonality — best & worst months Bafna Pharmaceuticals Limited — Technical setup — score, trend, support & resistance Bafna Pharmaceuticals Limited — Live exchange announcements
📋 High Promoter Holding Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹27 Cr
Sales · Jun 2026
-23.2% YoY
₹1 Cr
Operating Profit · Jun 2026
-82.6% YoY
3.3%
OPM % · Jun 2026
-77.4% YoY
₹0 Cr
Net Profit · Jun 2026
-97.8% YoY
₹0.03
EPS · Jun 2026
-97.9% YoY

📝 Bafna Pharmaceuticals Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Bafna Pharmaceuticals Limited reported revenue of ₹27 crore for the quarter ended June 2026 (Q1 FY27), down 23.2% from ₹35 crore in the same quarter last year, and down 37.1% sequentially over the March 2026 quarter.

Net profit fell 97.8% year-on-year to ₹0 crore, from ₹3 crore. Earnings per share (EPS) came in at ₹0.03.

Operating profit stood at ₹1 crore — an operating margin (OPM) of 3.3%, compared with 14.6% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Bafna Pharmaceuticals Limited posted revenue of ₹151 crore, a growth of 3.3% over FY25, with a net profit of ₹11 crore (up 166.8% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹143 crore with a net profit of ₹8 crore.

Valuation snapshot

At the current price of ₹461.35, BAFNAPH has a market capitalisation of ₹1,091 crore and a trailing P/E of about 140.2.

Within the Pharmaceuticals - Indian - Formulations industry, it is the 12th-largest of the 20 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 75.00%, foreign institutional investors (FIIs) 9.34%, public shareholders 15.66% of Bafna Pharmaceuticals Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹1,091 Cr
Current Price ?
₹461.4
P/E ?
140.19above ind
Industry P/E ?
21.30
P/B ?
11.37
P/S ?
7.65
P/FCF ?
-109.14
Enterprise Value ?
₹1,128 Cr
EV/EBITDA ?
95.94
PEG ?
N/A
Earnings Yield ?
0.5%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹143 Cr
OPM ?
8.2%
Profit after tax (TTM) ?
₹8 Cr
EPS (TTM) ?
₹3.29
ROCE ?
12.0%
ROE ?
8.1%
ROA ?
4.4%
Growth
Sales — latest qtr ?
₹27 Cr
PAT — latest qtr ?
₹0 Cr
YoY qtr sales growth ?
-23.2%
YoY qtr profit growth ?
-97.8%
Sales growth (3y) ?
9%
Sales growth (5y) ?
16%
Profit growth (3y) ?
0%
Profit growth (5y) ?
14%
Financial Health
Debt ?
₹37 Cr
Debt to Equity ?
0.39
Interest Coverage ?
2.7
Current Ratio ?
N/A
Ownership
Promoter holding ?
75.00%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
104.2%
Return 6 months ?
230.8%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 4242412841334033393535384227 -23.2% -37.1%
Operating Profit 864-23143354341 -82.6% -75.2%
Other Income 02011010-111122 +218.5% +8.6%
Interest 11011111111111 +3.0% -9.0%
Depreciation 21111122011222 +30.0% +7.3%
Profit Before Tax 662-31-131133230 -97.8% -97.1%
Net Profit 562-31-131133230 -97.8% -97.3%
EPS 2.342.681.05-1.240.62-0.301.110.400.551.431.320.781.160.03 -97.9% -97.4%
OPM % 18.0% 15.0% 9.9% -7.3% 7.0% 3.6% 9.4% 9.2% 8.0% 14.6% 12.1% 8.0% 8.4% 3.3% -77.4% -60.7%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹146 Cr ₹151 Cr ₹143 Cr +3.3%
Operating Profit ₹11 Cr ₹16 Cr ₹12 Cr +42.8%
OPM % 7.66% 10.59% 8.25% +38.3%
NPM % 2.85% 7.37% 5.46% +158.6%
Other Income ₹1 Cr ₹5 Cr ₹6 Cr +693.3%
Depreciation ₹5 Cr ₹6 Cr ₹6 Cr +23.9%
Interest ₹3 Cr ₹4 Cr ₹4 Cr +34.1%
EBIT ₹6 Cr ₹10 Cr ₹5 Cr +57.6%
PBT ₹4 Cr ₹11 Cr ₹8 Cr +165.2%
Tax — — — —
Net Profit ₹4 Cr ₹11 Cr ₹8 Cr +166.8%
EPS ₹1.76 ₹4.69 ₹3.29 +166.5%
Material Cost — — ₹14 Cr —
Employee Cost — — ₹6 Cr —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 24242424 +0.0%
Reserves 50576172 +18.0%
Borrowings 23242837 +32.1%
Other Liabilities 33424042 +5.0%
Total Liabilities 130148153176 +15.0%
Fixed Assets 40405982 +39.0%
CWIP 21273 -57.1%
Investments -0-0-0-0 —
Other Assets 88958791 +4.6%
Total Assets 130148153176 +15.0%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 592215 -31.8%
Cash from Investing Activity -7-15-21-22 -4.8%
Cash from Financing Activity 10-116 +500.0%
Net Cash Flow 8-62-1 -150.0%
Free Cash Flow -2-60-10 —
CFO/OP 32%87%194%96% -50.5%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 130109101106 +5.0%
Inventory Days 129125127129 +1.6%
Days Payable 165149140139 -0.7%
Cash Conversion Cycle 94848896 +9.1%
Working Capital Days 104927474 +0.0%
ROCE % 16%9%8%12% +50.0%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 75.00%75.00%75.00%75.00%75.00% +0.0%
FIIs 9.34%9.34%9.34%9.34%9.34% +0.0%
Public 15.66%15.66%15.66%15.66%15.66% +0.0%
No. of Shareholders 7,2837,5727,1196,9287,062 +1.9%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Formulations · 20 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SHILPAMED Shilpa Medicare ₹1,032.00 20,184 67.5 1,683 297 28.4% 17.7% 47.7% 454.9% 44.9% 115.2%
2 MARKSANS Marksans Pharma ₹332.50 15,068 29.1 3,171 521 22.5% 16.4% 12.5% 9.7% 35.6% 174.8%
3 BLISSGVS Bliss GVS ₹680.50 7,236 52.9 1,005 142 19.7% 14.1% 14.4% 48.7% 37.6% 15.8%
4 JSLL Jeena Sikho ₹507.55 6,309 26.7 852 236 42.6% 27.7% 17.1% 85.5% 28.8% 28.0%
5 SENORES Senores Pharmaceuticals ₹1,327.50 6,114 46.6 692 131 29.5% 19.0% 63.0% 108.7% 30.6% 43.8%
6 WINDLAS Windlas Biotech ₹1,129.50 2,331 35.7 942 66 11.1% 7.1% 18.9% 9.0% 18.1% -0.1%
7 VENUSREM Venus Remedies ₹1,651.10 2,210 19.0 811 117 20.4% 14.4% 17.9% 127.9% 35.6% 139.3%
8 SYNCOMF Syncom Formulations ₹23.44 2,203 1.3 12,547 1,729 15.2% 13.8% 2566.9% 3386.8% 7.4% 57.7%
9 HESTERBIO Hester Biosciences ₹2,187.90 1,861 13.6 318 137 30.8% 43.0% 4.7% 101.2% -8.4% 460.8%
10 AMRUTANJAN Amrutanjan Health ₹489.00 1,413 26.2 512 54 14.4% 10.5% 11.0% 1.3% 9.5% -45.4%
11 LINCOLN Lincoln Pharmaceuticals ₹601.50 1,205 12.5 694 97 14.6% 14.0% 7.6% 7.2% 15.1% 30.9%
12 BAFNAPH Bafna Pharmaceuticals ₹301.45 713 91.6 143 8 8.2% 5.5% 3.3% 166.8% -23.2% -97.8%
13 KILITCH Kilitch Drugs ₹198.00 692 16.1 237 29 15.3% 12.3% 18.7% 20.1% 4.0% -13.0%
14 MEDICAMEQ Medicamen Biotech ₹323.80 439 1.3 9,516 381 10.1% 4.0% 5751.8% 3308.0% 11.3% 15.3%
15 QUESTLAB Quest Laboratories ₹137.50 225 13.7 150 16 12.7% 11.0% 25.8% 34.9% -30.2% 47.9%
16 JFLLIFE Jfl Life ₹51.05 168 24.7 131 7 9.1% 5.2% 60.2% 53.1% -4.2% 48.5%
17 ZENITHDRUG Zenith ₹78.45 135 41.7 171 4 7.0% 2.3% — — 40.9% 100.0%
18 ALPA Alpa Laboratories ₹62.32 131 29.6 111 4 1.7% 4.0% -5.9% -22.5% 25.2% -91.7%
19 MEDIORG Medicamen ₹101.45 119 — 22 -3 -12.9% -14.0% — — -77.5% -383.0%
20 BIOFILCHEM Biofil Chemicals ₹33.13 54 110.4 34 0 2.3% 1.4% -15.0% 405.5% 92.1% -95.5%
❓ Frequently asked questions
What was Bafna Pharmaceuticals Limited's revenue in Q1 FY27?
Bafna Pharmaceuticals Limited reported revenue of ₹27 crore for the quarter ended June 2026 (Q1 FY27), down 23.2% from ₹35 crore in the same quarter last year, and down 37.1% sequentially over the March 2026 quarter.
What was Bafna Pharmaceuticals Limited's net profit in Q1 FY27?
Net profit fell 97.8% year-on-year to ₹0 crore, from ₹3 crore. Earnings per share (EPS) came in at ₹0.03.
What is BAFNAPH's market capitalisation and P/E ratio?
At the current price of ₹461.35, BAFNAPH has a market capitalisation of ₹1,091 crore and a trailing P/E of about 140.2.
Who owns Bafna Pharmaceuticals Limited? (shareholding pattern)
As of Jun 2026, promoters held 75.00%, foreign institutional investors (FIIs) 9.34%, public shareholders 15.66% of Bafna Pharmaceuticals Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI